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An autochthonous model of pancreatic ductal adenocarcinoma
(PDA) permitted the analysis of why immunotherapy is ineffective
in this human disease. Despite ﬁnding that PDA-bearing mice had
cancer cell-speciﬁc CD8+ T cells, the mice, like human patients with
PDA, did not respond to two immunological checkpoint antago-
nists that promote the function of T cells: anti-cytotoxic T-lympho-
cyte-associated protein 4 (α-CTLA-4) and α-programmed cell death
1 ligand 1 (α-PD-L1). Immune control of PDA growth was achieved,
however, by depleting carcinoma-associated ﬁbroblasts (CAFs)
that express ﬁbroblast activation protein (FAP). The depletion of
the FAP+ stromal cell also uncovered the antitumor effects of
α-CTLA-4 and α-PD-L1, indicating that its immune suppressive activ-
ity accounts for the failure of these T-cell checkpoint antagonists.
Three ﬁndings suggested that chemokine (C-X-C motif) ligand 12
(CXCL12) explained the overriding immunosuppression by the FAP+
cell: T cells were absent from regions of the tumor containing cancer
cells, cancer cells were coated with the chemokine, CXCL12, and the
FAP+ CAF was the principal source of CXCL12 in the tumor. Admin-
istering AMD3100, a CXCL12 receptor chemokine (C-X-C motif) re-
ceptor 4 inhibitor, induced rapid T-cell accumulation among
cancer cells and acted synergistically with α-PD-L1 to greatly di-
minish cancer cells, which were identiﬁed by their loss of hetero-
zygosity of Trp53 gene. The residual tumor was composed only of
premalignant epithelial cells and inﬂammatory cells. Thus, a single
protein, CXCL12, from a single stromal cell type, the FAP+ CAF,
may direct tumor immune evasion in a model of human PDA.
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Immunotherapy of cancer has made recent progress by focusingon overcoming T-cell immunological checkpoints with block-
ing monoclonal antibodies to cytotoxic T-lymphocyte associ-
ated protein-4 (CTLA-4) and the programmed cell death 1/
programmed cell death 1 ligand 1 (PD-1/PD-L1) receptor/ligand
pair (1–7). Many patients, however, did not respond to these
immunological checkpoint antagonists for reasons that are not
understood. In particular, patients with pancreatic ductal adeno-
carcinoma (PDA), the fourth most common cause of cancer-related
deaths in the United States, had no objective responses to anti
(α)-CTLA-4 (7) or α-PD-L1 monoclonal antibodies (5).
A mesenchymal tumoral stromal cell that is present in almost
all human adenocarcinomas (8) and is identiﬁed by its expression
of the membrane protein, ﬁbroblast activation protein (FAP),
was shown recently to mediate immunosuppression in a trans-
planted murine tumor model (9). Because FAP+ stromal cells
are present in human PDA (8), we wished to investigate whether
the immunosuppressive activity of the murine FAP+ stromal cell
might be involved in the resistance of this cancer to immuno-
therapy. We were able to carry out this analysis because of the
availability of the autochthonous LSL-KrasG12D/+;LSL-Trp53R172H/+;
Pdx-1-Cre (KPC) model of PDA (10). We ﬁnd that this PDAmodel
replicates the resistance of human PDA to checkpoint antagonists,
despite the presence of systemic anti-PDA immunity. The failure
of immune surveillance is attributable to local immunosuppression
mediated by the FAP+ stromal cell, which comprises essentially
all carcinoma-associated ﬁbroblasts (CAFs). Immunosuppression
manifests as exclusion of T cells from regions of the tumor con-
taining cancer cells and involves the production of chemokine
(C-X-C motif) ligand 12 (CXCL12) by FAP+ CAFs. Inhibiting
chemokine (C-X-C motif) receptor 4 (CXCR4), a CXCL12 re-
ceptor, promotes T-cell accumulation and synergizes with the
checkpoint antagonist, α-PD-L1, to cause cancer regression.
Results and Discussion
In the KPC model, Cre-mediated expression of Trp53R172H and
KrasG12D is targeted to the pancreas, causing the development of
Signiﬁcance
Cancer immune evasion is well described. In some cases, this
may be overcome by enhancing T-cell responses. We show that
despite the presence of antitumor T cells, immunotherapeutic
antibodies are ineffective in a murine pancreatic cancer model
recapitulating the human disease. Removing the carcinoma-
associated ﬁbroblast (CAF) expressing ﬁbroblast activation
protein (FAP) from tumors permitted immune control of tumor
growth and uncovered the efﬁcacy of these immunothera-
peutic antibodies. FAP+ CAFs are the only tumoral source of
chemokine (C-X-C motif) ligand 12 (CXCL12), and administering
AMD3100, an inhibitor of chemokine (C-X-C motif) receptor 4,
a CXCL12 receptor, also revealed the antitumor effects of an
immunotherapeutic antibody and greatly diminished cancer
cells. These ﬁndings may have wide clinical relevance because
FAP+ cells are found in almost all human adenocarcinomas.
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invasive and metastatic carcinoma that recapitulates many aspects
of human PDA, including the loss of heterozygosity (LOH) of
Trp53 in cancer cells but not in premalignant pancreatic intra-
epithelial neoplasia (PanIN) (10). KPC mice with appropriately
sized tumors demonstrate consistent tumor growth, which per-
mits robust analyses of experimental interventions (SI Appendix,
Fig. S1). We examined whether blocking immunological check-
points with α-CTLA-4 and α-PD-L1 would promote immune
control of the tumor. Administering these antibodies over 6 d to
mice bearing PDA did not diminish the ∼80% increase in tumor
volume observed in mice receiving control IgG (Fig. 1A). We
determined whether this could be explained by the absence of an
immune response to the PDA. Splenic CD8+ T cells from PDA-
bearing and non–tumor-bearing mice were stimulated with tu-
mor cells, and IFN-γ–secreting CD8+ T cells reporting antigenic
stimulation were detected in an enzyme-linked immunosorbent
spot (ELISpot) assay. Tumor cells induced signiﬁcantly more
ELISpots among CD8+ T cells from tumor-bearing mice than from
non–tumor-bearing mice (Fig. 1B). The frequency of IFN-γ–
secreting CD8+ T cells was the same when the stimulating tumor
cells were from the T-cell donor or from another PDA-bearing
mouse (Fig. 1C). An established PDA cell line also was stimula-
tory, whereas dissociated cells from pancreata of LSL-KrasG12D/+;
Pdx-1-Cre mice with premalignant PanIN lesions expressing only
KrasG12D or from young KPC mice before the development of
cancer, were not (Fig. 1D and SI Appendix, Fig. S2). Therefore,
PDA-bearing mice have a spontaneous adaptive immune response
to antigens that are shared by cancer cells from different PDA
tumors, and the ineffectiveness of α-CTLA-4 and α-PD-L1 sug-
gests an additional immunosuppressive mechanism.
We considered the possibility that the FAP+ stromal cell
mediates this immunosuppression. FAP+ cells were present in
PanIN and both cytokeratin-19+ (CK19+) and CK19− PDA lesions
(Fig. 2A). FAP+ cells in PanIN expressed CD34 (SI Appendix, Fig.
S3 A and B) but rarely α-smooth muscle actin (αSMA) (Fig. 2B),
whereas FAP+ cells among PDA cells were CD34− (SI Appendix,
Fig. S3B) and αSMA+ (Fig. 2B). All FAP+ cells were PDGF
receptor-α+ (SI Appendix, Fig. S3A) and CD45− (Fig. 2C), con-
ﬁrming their mesenchymal origin, and their frequency among dis-
persed tumor cells was 3.7% [95% conﬁdence interval (CI): 1.1–
6.3%; n = 8]. The expression of FAP by 92% of the αSMA+
ﬁbroblasts (95% CI: 87.5–97.1%; n = 5) suggested that they are
CAFs. This suggestion was supported by the transcriptomes
of CD34+FAP+ (PanIN-associated) and CD34−FAP+ (PDA-
associated) cells (Fig. 2D), which exhibited the “inﬂammatory
gene signature” of CAFs (11). FAP+ cells from three normal tissues
also displayed the signature and were clustered together by a
principal component analysis of their transcriptomes (SI Appendix,
Fig. S3C), indicating that FAP may identify a stromal cell lineage.
The increased expression by tumoral FAP+ cells of genes encoding
extracellular matrix proteins veriﬁes their role in the desmo-
plasia of PDA, whereas their lower expression of decorin may
relate to similar observations in human cancer (Fig. 2D).
We introduced into the KPC line the bacterial artiﬁcial chro-
mosome (BAC) transgene containing a modiﬁed Fap gene that
drives the expression of the human diphtheria toxin receptor (DTR)
selectively in cells that are FAP+ (9). Administering diphtheria toxin
(DTx) to PDA-bearing BAC transgenic mice depleted ∼55% the
tumoral FAP+ cell content (Fig. 3A). DTx appeared to deplete
FAP+ cells throughout the tumor. Depleting FAP+ cells slowed
PDA growth (Fig. 3B), but not when CD4+ and CD8+ T cells were
removed (Fig. 3C). Combining depletion of FAP+ cells with ad-
ministration of α-CTLA-4 or α-PD-L1 further diminished tumor
growth (Fig. 3D and E), indicating that the FAP+ cell contributes to
the resistance of murine PDA to these checkpoint antagonists. The
absence of an increase in IFN-γ–secreting CD8+ T cells from
the spleens of DTx- and α-PD-L1–treated mice indicates that
immune control was not accomplished by enhanced priming of
cancer-speciﬁc CD8+ T cells (SI Appendix, Fig. S2).
Therapy involving the depletion of FAP+ cells is precluded by
their essential roles in normal tissues (12), and a therapeutic
target that accounts for their immunosuppression had to be
identiﬁed. We noted a paucity of CD3+ T cells in the vicinity of
cancer cells (Fig. 4A), a characteristic of human PDA that is
associated with FAP+ cells (SI Appendix, Fig. S4) and other
carcinomas (13, 14). This T-cell trafﬁcking problem directed at-
tention to the chemokine, CXCL12, which localizes to cancer cells
in both human (15) (SI Appendix, Fig. S4) and murine (Fig. 4B)
PDA. We identiﬁed the source of CXCL12 as the tumoral FAP+
cell (Fig. 4C), as has been previously reported for CAFs (16).
FAP+ cells in the s.c. Lewis lung carcinoma (LL2) model also are
the tumoral source of CXCL12 (SI Appendix, Fig. S5A). CXCR4 is
unlikely to mediate the uptake of the chemokine because cancer
cell expression of CXCR4 is low (SI Appendix, Fig. S6). We hy-
pothesize that high mobility group box 1 (HMGB1), which is
overexpressed and secreted by metabolically stressed cancer cells
(17), captures CXCL12 by forming a high-afﬁnity heterocomplex
(18), thus explaining the paradoxical localization of CXCL12 on
cancer cells despite their not producing CXCL12 (Fig. 4C).
To assess the role of CXCL12 in tumoral immunosuppression,
we administered AMD3100, a speciﬁc CXCR4 inhibitor that is
licensed for clinical use (19), to mice bearing PDA in the presence
or absence of depleting antibodies to CD4+ and CD8+ T cells.
Tumor growth was slowed by AMD3100 in a T cell-dependent
manner (Fig. 5A). AMD3100 also induced T cell-dependent
control of s.c. immunogenic LL2 tumors (SI Appendix, Fig. S5 B
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Fig. 1. Immunological characteristics of murine
PDA. (A) Increase in PDA volume (mean ± SEM)
following treatment of mice with α-PD-L1 (n = 6),
α-CTLA-4 (n = 6), or control (n = 4) antibodies was
measured by ultrasound. (B–D) Induction of IFN-γ
secretion by splenic CD8+ T cells from various donor
types following stimulation by different sources of
pancreatic cells was measured by ELISpot assay (n ≥
8 in B and D; Mann–Whitney test, n = 4 in C). *P <
0.05; ***P < 0.001.
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and C). We administered a higher dose of AMD3100 that al-
most completely arrested PDA growth and combined it with
immunological checkpoint antagonists (Fig. 5 B and C). The com-
bination of AMD3100 with α-PD-L1 led to a signiﬁcant 15% decline
in PDA volume by 48 h and no further decrease over the following 4
d. α-CTLA-4 did not augment the antitumor effect of AMD3100.
Rapid, therapy-induced, clinically relevant reductions in cancer
cell number are often not associated with comparable decreases in
B
C
0 102 103 104 105
0
102
103
104
105 0.0%
0 102 103 104 105
0
102
103
104
105 6.3%
CD45
FA
P
Is
ot
yp
e
FAP SMA DAPI p53            DAPI
PanIN
PDA
A
100 m 100 m
100 m 100 m
100 m 100 m 100 m
PanIN PDA PDA
p53 FAP CK19 DAPI
D
Pancreas
12 11 27 220 399
0 0 1 26 13
61 107 705 771 377
455 991 2854 2176 1130
10 33 142 319 139
24 121 72 135 234
535 274 121 259 447
164 5 0 876 7621
3 4 2 26 44
22 29 39 122 200
279 478 392 907 834
43 91 32 473 931
263 395 499 419 1007
4925 5888 7828 1417 830
Muscle Adipose
PanIN
CD34+
PDA
CD34-
Acta2
IL-6
Cxcl1
Cxcl2
Ptgs2
Cyr61
Spp1
Lox
Col1a1
Ctgf
Fn1
Dcn
In
fla
m
m
at
or
y
Si
gn
at
ur
e
D
es
m
op
la
sia
low      high
IL-1β
Tgf 1β
Fig. 2. Characterization of FAP+ stro-
mal cells in murine PDA. (A) Tissue sec-
tions from PDA tumors were stained for
FAP, CK19, and p53 and then analyzed
by immunoﬂuorescent (IF) microscopy.
White arrows indicate examples of p53+
LOH cells. (B) Tissue sections from PDA
tumors were stained for αSMA and FAP
and analyzed by IF microscopy. (C) Sin-
gle-cell suspensions of PDA tumor cells
were analyzed by ﬂow cytometry. (D)
Heat map presents the reads per kilo-
base of transcript per million mapped
reads of RNA-seq analyses of FACS-pu-
riﬁed FAP+ cells.
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Fig. 3. Conditional depletion of FAP+ stromal cells
and immune control of PDA. (A) KPCD mice with
PDA received DTx or PBS; after 6 d, tumoral Fap
mRNA was measured by quantitative RT-PCR (qRT-
PCR) (PBS, n = 5; DTx, n = 7). (B) KPC mice with or
without the DTR BAC transgene received DTx or PBS,
and tumor volumes were measured by ultrasound
(PBS, n = 6; DTx, n = 8; DTx to non-DTR transgenic,
n = 4). (C) KPCD mice with PDA received CD4- and
CD8-depleting antibodies or control IgG before and
during treatment with DTx or PBS. Tumor volumes
were measured (α-CD4/8 + PBS, n = 3; α-CD4/8 + DTx,
n = 5; isotype IgG + DTx, n = 5). (D) KPCD mice with
PDA received α-CTLA-4 or α-PD-L1 during treatment
with DTx or PBS, and tumor volumes were measured
[DTx, n = 13 (representing all DTx-treated KPCD mice
presented in B and C); α-CTLA-4+DTx, n = 6; α-PD-L1 +
DTx, n = 4]. (E ) Waterfall plots demonstrate the
ﬁnal tumor volume changes in individual mice. Dashed
lines indicate the mean tumor volume for each treat-
ment group. *P < 0.05; **P < 0.01.
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tumor volume (20). To evaluate more deﬁnitively the response of
the PDA to immunotherapy, we examined tumors after 6 d of
treatment for the presence of cancer cells. These can be unam-
biguously identiﬁed because their loss of the wild type p53 allele
results in the appearance and stabilization of the protein product
of the mutant p53R172H allele (10). These p53+ PDA cells were
abundant in tumors from mice that had received PBS or α-PD-L1
but were greatly diminished in tumors from mice that had received
AMD3100 alone or with α-PD-L1 (Fig. 5D and SIAppendix, Fig. S7).
The marked decrease in Ki67+ cells reﬂects this diminution in pro-
liferating cancer cells (Fig. 5E and SI Appendix, Fig. S4). Serial sec-
tions demonstrate that the residual tumorswere composed of CK19+
epithelial cells and CD45+ inﬂammatory cells (Fig. 5F). The se-
lective elimination of p53+LOH cells is consistent with the ﬁnding
that the CD8+ T-cell response is cancer cell-speciﬁc (Fig. 1D).
To determine if this immunotherapeutic effect was caused by en-
hanced T-cell accumulation among cancer cells, we treated mice for
24 h with AMD3100 and α-PD-L1. α-PD-L1 alone had no effect,
whereas AMD3100 increased the accumulation of T cells (Fig. 6
and SI Appendix, Fig. S9A). The combination of α-PD-L1 with
AMD3100 ampliﬁed this effect and led to an apparent decrease in
the frequency of p53+ LOH cancer cells (Fig. 6 and SI Appendix,
Fig. S9A). Local T-cell proliferation could not account for the
increase in tumoral T cells, because there were few Ki67+ CD3+
cells in AMD3100- and α-PD-L1–treated tumors (mean of 1.58%;
range: 0.75–2.99%; n = 3) (SI Appendix, Fig. S9B). Furthermore,
because Foxp3+ cells also were increased in tumors of mice given
AMD3100 and α-PD-L1 (SI Appendix, Fig. S9C), we conclude that
regulatory T (Treg) cells are not critically involved once immuno-
suppression by CXCR4/CXCL12 and PD-1/PD-L1 is overcome.
These studies reveal a hierarchy of immunosuppression in mu-
rine PDA, with that mediated by the FAP+ CAF being dominant
over two T-cell checkpoints. Depleting the FAP+ stromal cell or
inhibiting the interaction of its chemokine, CXCL12, with
CXCR4 uncovers the antitumor activity of α-CTLA-4 and α-PD-L1.
We do not know whether CXCR4-mediated exclusion of T cells
reﬂects T-cell apoptosis, as occurs with HIV gp120 (21), or a che-
morepulsive effect of CXCL12 (22). A direct effect of AMD3100
on cancer cells, however, is excluded by their not expressing CXCR4
(SI Appendix, Fig. S6). The absence of a synergistic interaction
between AMD3100 and α-CTLA-4 may indicate that inhibiting
CXCR4 so strongly promotes the accumulation of T cells among
cancer cells such that any augmented priming by α-CTLA-4 is su-
perﬂuous. We excluded the possibility that other mechanisms may
have accounted for the absence of an effect of α-CTLA-4 in
combination with AMD3100. The α-CTLA-4 clone, 9H10,
that was used in this experiment depletes Treg cells (23) and
was effective when combined with a suboptimal reduction of
FAP+ CAFs in PDA-bearing mice (Fig. 3A). Furthermore, mac-
rophages that are capable of engaging in Fc receptor-mediated
Treg cell clearance (23) were abundant in tumors treated with
AMD3100 (SI Appendix, Fig. S10). Finally, the ﬁnding that Treg
cells even accumulated in tumors along with other CD3+ cells
during treatment with AMD3100 and α-PD-L1 (SI Appendix, Fig.
S9C) suggests that the inhibitory function of Treg cells only plays
a minor role once the immune suppressive effect of CXCL12 is
neutralized. Hence, it is plausible that immune control of PDA
may be achieved without incurring the severe adverse effects of
α-CTLA-4 that have been observed in human patients with mel-
anoma, especially when coadministered with another T-cell
checkpoint antagonist (6).
BecauseTcells are also excluded fromother carcinomas (14, 15) in
which FAP+ stromal cells are abundant (8) and CXCL12 is associ-
ated with cancer cells (24), our ﬁndings may be widely relevant to
tumor immunotherapy. Finally, this study strongly supports the use
of autochthonous, genetically engineered models of cancer to
study the mechanisms of escape from immune surveillance.
These models have permitted the demonstration that cancers
may maintain the expression of antigens despite the occurrence
of systemic immune responses (25) and that metastatic lesions
may be immunologically controlled despite outgrowth of primary
tumors (26), observations that focus attention on the need to un-
derstand fully the rules of tumoral immunosuppression.
Materials and Methods
Mice. All experiments were performed in accordance with institutional
guidelines and were approved by the UK Home Ofﬁce and the animal ethics
committee of Cancer Research UK Cambridge Institute and the University
of Cambridge. The generation of KPC and FAP-DTR BAC transgenic mice has
been described previously (9, 10). These strains were crossed to generate
KPCD (LSL-KrasG12D/+;LSL-Tp53R172H/+;Pdx-1-Cre;FAP-DTR) mice. Tumors that
were 6–9mm in diameter were selected, and volumes weremonitored by high-
resolution ultrasound as detailed in SI Appendix. KPC (±DTR transgene) mice
were treated every 48 h with 25 ng/g of DTx (List Biologicals) in PBS, 160 μg of
α-PD-L1 (10F.9G2; Biolegend), 100 μg of α-CTLA-4 (9H10; Biolegend), or iso-
type control antibody by i.p. injection. AMD3100 (Sigma–Aldrich) was ad-
ministered bymeans of anAZLET osmotic pump (Charles River) at 30mg/mL or
90mg/mL (high dose). For T-cell depletion,mice received 300 μg each of α-CD4
(GK1.5; Biolegend) and α-CD8α (53-6.7; Biolegend) or isotype control anti-
bodies for 3 consecutive days before treatment and on days 2 and 5 of
treatment via i.p. injection. For s.c. tumors, 2 × 105 LL2/ovalbumin (OVA) cells
were injected into the ﬂanks of C57BL/6 and mouse strain Rag2−/− mice. Tu-
mor volumes were calculated from caliper measurements using a standard
formula listed in SI Appendix. AMD3100 (30 mg/mL) treatment via the AZLET
osmotic pump commenced when tumors reached at least 62 mm3.
Cell Lines. The generation of the LL2 cell line expressing chicken OVA (LL2/OVA)
has been previously reported (9). Pancreatic cancer cell lines were derived from
tumors arising in KPC mice (TB32964, K8484).
ELISpot Assays. Single-cell suspensions of CD8+ splenocytes and of whole tumors
depleted of CD3e+ T cells were puriﬁed by magnetic-activated cell separation as
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Fig. 4. FAP+ cell-derived CXCL12 and T-cell exclu-
sion. (A) Tissue sections from PDA tumors were
stained for CD3, p53, and CD11b and then analyzed
by IF microscopy. White arrows demonstrate exam-
ples of CD3+ cells. (B) Tissue sections from PDA
tumors were stained for CXCL12 and p53 and ana-
lyzed by IF microscopy. (C) Single-cell suspensions of
PDA tumors (n = 3) were stained with antibodies for
FAP, CD45, and CD11b. FAP+ cells, CD11b+ cells, and
PDA/PanIN cells (FAP−CD45−CD11b−) were FACS-pu-
riﬁed. Their levels of Cxcl12 mRNA were assessed by
qRT-PCR. *P < 0.05.
Feig et al. PNAS | December 10, 2013 | vol. 110 | no. 50 | 20215
M
ED
IC
A
L
SC
IE
N
CE
S
described in SI Appendix. T cells were challenged with stimulator cells in a 12-h
IFN-γ release ELISpot assay. IFN-γ–secreting CD8+ T-cell frequency was calculated
from a dose–response curve.
Immunoﬂuorescence. Frozen tissue sections were prepared and imaged by
confocal microscopy as described in SI Appendix. Slides of p53+ cells and Treg
cells were analyzed on the ARIOL XT (Leica Biosystems) system.
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Fig. 5. Inhibition of CXCR4 by AMD3100 and immune elimination of PDA cells. (A) PDA-bearing mice, some of which had been pretreated with
depleting CD4 and CD8 antibodies or control IgG, received PBS or AMD3100 by continuous infusion, and tumor volumes were measured by ultrasound
(PBS, n = 5; AMD3100 + isotype IgG, n = 6; AMD3100 + α-CD4/8, n = 4). (B) PBS or AMD3100 (high dose) was given to PDA-bearing mice that
were treated with α-CTLA-4, α-PD-L1, or control IgG (AMD3100 high + α-CTLA-4, n = 4; AMD3100 high + α-PD-L1, n = 7; AMD3100 high + isotype IgG,
n = 6). (C ) Waterfall plots present the ﬁnal changes in tumor volumes in individual mice from A and B. Dashed lines indicate the mean tumor volume
for each treatment group. (D) Tissue sections from PDA tumors taken from mice treated with PBS or AMD3100 high + α-PD-L1 for 6 d were stained for
p53, and the entire cross-sections were imaged. White squares show the regions corresponding to the magniﬁed images. Tissue sections from PDA
tumors of mice treated with AMD3100 high + α-PD-L1 or PBS for 6 d were stained for Ki67 (E ) or CD45 and CK19 (F ) and analyzed by IF microscopy.
*P < 0.05; **P < 0.01.
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Immunohistochemistry. Slides were prepared as described in SI Appendix and
imaged on the ARIOL XT system.
Flow Cytometry/Cell Sorting. Single-cell suspensions were prepared by tissue
digestion, stained, and analyzed as described in SI Appendix.
RNA Analysis. RNAwas extracted fromwhole-tumor samples and sorted cells
as described in SI Appendix. For RT-PCR, we used Taqman assays, as de-
tailed in SI Appendix. Data were normalized to endogenous Tbp. For anal-
ysis of Fap fold change, data were further normalized to the mean of the
control group.
RNA-Sequencing and Computational Methods. Cell sorting, RNA extraction,
and sequencing were performed as previously described (12). Computational
analysis is described in SI Appendix. The RNA-sequencing data generated in
this investigation were deposited in the National Center for Biotechnology
Information’s Gene Expression Omnibus (GEO) database and can be accessed
using GEO accession no. GSE42605.
Statistical Analyses. For multiple comparisons, ANOVA with Bonferroni’s
post hoc test was applied. Signiﬁcance was otherwise determined using the
Student t test, unless speciﬁed in individual ﬁgure legends. Data are presented
as the mean ± SEM. Statistical comparison of growth curves was per-
formed using a permutation-based, pairwise test (SI Appendix).
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